A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.

The following policies are not for routine commissioning.

• 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed-tomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)
• Alglucosidase alfa for patients with infantile-onset Pompe disease (all ages)
• Amifampridine phosphate for the treatment of Lambert-Easton myasthenic syndrome
• Argus II retinal prosthesis for retinitis pigmentosa
• Autologous chrondrocyte implantation for osteochondral lesions of the talus (adults)
• Bendamustine for relapsed multiple myeloma (all ages)
• Bortezomib for relapsed/refractory mantle cell lymphoma
• Bortezomib for relapsed / refractory Waldenstrom’s Macroglobulinaemia (all ages)
• Bortezomib for the treatment of refractory antibody mediated rejection post kidney transplant
• Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab
• Chemosaturation for liver metastases from ocular melanomas
• Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation
• Continuous aztreonam lysine for cystic fibrosis (all ages)
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma
• Deep brain stimulation for central post stroke pain
• Deep brain stimulation for chronic neuropathic pain
• Deep brain stimulation for refractory epilepsy
• Deep brain stimulation for refractory Tourette Syndrome (adults)
• Direct skeletal fixation for transfemoral limb loss (adults)
• Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
• Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant
• Everolimus for prevention of organ rejection following heart transplantation
• Extra corporeal membrane oxygenation service for adults with cardiac failure
• Fampridine for multiple sclerosis
• Gastroelectrical stimulation for gastroparesis
• High definition silicone covers for prosthetic limbs, high definition feet and partial hand prosthesis
• Hyperbaric oxygen therapy for carbon monoxide poisoning (all ages)
• Hyperbaric oxygen therapy for diabetic lower limb ulceration (diabetic foot ulcer) (all ages)
• Hyperbaric oxygen therapy for malignant otitis externa (all ages)
• Hyperbaric oxygen therapy for necrotising soft tissue infections (all ages)
• Hyperbaric oxygen therapy for soft tissue radiation damage in patients with a history of pelvic irradiation for malignant disease (all ages)
• Idebenone for treating people over 12 years of age with Leber’s Hereditary Optic Neuropathy
• Infliximab (remicade) as anti-TNF Alpha treatment option for paediatric patients with severe refractory uveitis
• Infliximab for Progressive Pulmonary Sarcoidosis in adults
• Infliximab for the treatment of hidradenitis suppurativa
• Intrathecal pumps for treatment of severe chronic pain
• Non-invasively lengthened spinal rods for scoliosis
• Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)
• Pasireotide for acromegaly as third-line treatments (adults)
• Personalised external aortic root support for surgical management of enlarged aortic root
• Proton beam therapy for breast cancer (all ages)
• Proton beam therapy for cancer of the prostate
• Proton Beam Therapy for Lung Cancer (Adults)
• Renal denervation for resistant hypertension
• Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system & IgM paraprotein-associated demyelinating neuropathy (adults)
• Rituximab for connective tissue disease associated with interstitial lung disease
• Rituximab for the treatment of primary Sjogren’s syndrome in adults
• Robotic assisted lung resection for primary lung cancer
• Robotic assisted surgery for bladder cancer
• Robotic assisted surgery for oesophago-gastric cancers
• Robotic assisted trans-oral surgery for throat and voice box cancers
• Sapropterin for phenylketonuria (all ages)
• Selective internal radiation therapy (SIRT) for the treatment of chemotherapy refractory or intolerant, unresectable primary intrahepatic cholangiocarcinoma (all ages)
• Stereotactic ablative radiotherapy (SABR) for patients with previously irradiated, locally recurrent para-aortic tumours (All ages)
• Stereotactic ablative radiotherapy as a treatment option for patients with hepatocellular carcinoma or cholangiocarcinoma
• Stereotactic ablative radiotherapy as a treatment option for patients with oligometastatic disease
• Stereotactic ablative radiotherapy as a treatment option for patients with renal cancer
• Stereotactic ablative radiotherapy in the treatment of previously irradiated tumours of the pelvis, spine and nasopharynx
• Stereotactic ablative radiotherapy in the treatment of prostate cancer
• Stereotactic radiosurgery for adults with Parkinson’s tremor and familial essential tremor
• Surgery for pectus deformity (all ages)
• Telotristat for treating carcinoid syndrome diarrhoea (adults)
• Temperature controlled laminar airflow device for persistent allergic asthma
• Teriparatide for the treatment of osteogenesis imperfecta (adults)
• Ustekinumab for refractory Crohn’s disease in pre-pubescent children
• Vedolizumab for refractory ulcerative colitis in pre-pubescent children
• Vertebral body tethering for scoliosis (age 8-18 years)